Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ZN-A-1041 |
| Synonyms | |
| Therapy Description |
ZN-A-1041 inhibits ERBB2 (HER2)-mediated downstream signaling, potentially resulting in tumor cell death (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZN-A-1041 | ZN-A 1041|ZN-A1041 | HER2 Inhibitor 44 | ZN-A-1041 inhibits ERBB2 (HER2)-mediated downstream signaling, potentially resulting in tumor cell death (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05593094 | Phase Ib/II | ZN-A-1041 Pertuzumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf + Trastuzumab + ZN-A-1041 Ado-trastuzumab emtansine + ZN-A-1041 Trastuzumab deruxtecan + ZN-A-1041 Pertuzumab + Trastuzumab + ZN-A-1041 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | Active, not recruiting | USA | NZL | ITA | GBR | FRA | ESP | AUS | 0 |